Comparison of pre-treatment with different diluted sufentanil in reducing propofol injection pain in gastrointestinal endoscopy: A randomized controlled study
PLOS One · 2025
DOI: 10.1371/journal.pone.0325113 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift PLOS One, 2025. Verfasst von Qian Su und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Nantong First People's Hospital, Nantong, Jiangsu, China. Hauptthemen laut MEDLINE: Propofol, Sufentanil, Endoscopy, Gastrointestinal, Pain. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Nantong Municipal Commission of Health and Family Planning, The High-Level Scientific Research Project Cultivation Fund of Nantong First People's Hospital, Nantong Municipal Science and Technology Bureau.
Abstract (Originalsprache)
Background
This study aimed to investigate the efficacy of pre-treatment with different concentrations of sufentanil in mitigating propofol injection-induced pain.
Methods
This study included 421 patients who were scheduled for gastrointestinal endoscopy between June 2023 and December 2024. Participants were randomly assigned to one of the four groups with different concentrations sufentanil: 0 µg/mL group(0.9% normal saline), 0.5 µg/mL group, 1 µg/mL group and 5 µg/mL group.
Results
Among the four groups, the rates of pain relief were 82 (77.4%), 93 (89.4%), 96 (89.7%), and 91 (87.5%), respectively. Compared to the 0 µg/mL group, the other groups demonstrated significantly reduced pain following propofol injection (p < 0.05). The recovery times were 14.59 ± 3.92 min, 15.13 ± 3.20 min, 14.27 ± 3.06 min, and 15.57 ± 3.24 min, respectively. Notably, the 1 µg/mL group did not exhibit a prolonged recovery time compared to the 0 µg/mL group. The total propofol consumption was recorded as 218.5 ± 36.8 mg, 196.7 ± 31.0 mg, 183.8 ± 25.0 mg, and 189.6 ± 31.4 mg, respectively, with the 1 µg/mL group showing the lowest total propofol consumption among the groups. The incidences of adverse events (AEs) were 61.3%, 70.2%, 58.9%, and 76.9%, respectively. In comparison to the 1 µg/mL group, the 5 µg/mL group exhibited a higher incidence of AEs. Furthermore, multivariate analysis indicated that a 5 µg/mL dilution of sufentanil increases the risk of AEs (p < 0.05).
Conclusions
The 1 µg/mL group demonstrated greater safety and efficacy when combined with propofol.
Trial registration
The study has been registered in the Chinese Clinical Trial Registry (ChiCTR). Link of the registry: http://www.chictr.org.cn . Date of registration: 2023/06/12. Trial registration number: ChiCTR2300072402.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Nantong First People's Hospital, Nantong, Jiangsu, China.
- Department of Epidemiology and Biostatistics, School of Public Health, Nantong University, Nantong, Jiangsu, China.
ORCID-Profile: Lei Yao
Förderung
- Nantong Municipal Commission of Health and Family Planning
- The High-Level Scientific Research Project Cultivation Fund of Nantong First People's Hospital
- Nantong Municipal Science and Technology Bureau
Zitieren
APA
Su, Q., He, S., Li, L., Wei, X., Sun, X., Yang, X., Du, B., & Yao, L. (2025). Comparison of pre-treatment with different diluted sufentanil in reducing propofol injection pain in gastrointestinal endoscopy: A randomized controlled study. PLOS One. https://doi.org/10.1371/journal.pone.0325113
Vancouver
Su Q, He S, Li L, Wei X, Sun X, Yang X, et al. Comparison of pre-treatment with different diluted sufentanil in reducing propofol injection pain in gastrointestinal endoscopy: A randomized controlled study. PLOS One. 2025. doi:10.1371/journal.pone.0325113
BibTeX
@article{Su2025,
author = {Su, Qian and He, Shu and Li, Lu and Wei, Xiangqing and Sun, Xin and Yang, Xuefeng and Du, Boxiang and Yao, Lei},
title = {Comparison of pre-treatment with different diluted sufentanil in reducing propofol injection pain in gastrointestinal endoscopy: A randomized controlled study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0325113}
}
EUVIMED